Published in J Control Release on December 28, 2015
Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery. Small (2016) 0.75
Targeting Selectins and Their Ligands in Cancer. Front Oncol (2016) 0.75
Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle. Sci Rep (2017) 0.75
Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells. Cell Mol Bioeng (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Cancer-related inflammation. Nature (2008) 34.21
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol (2008) 2.57
Prostate cancer screening and the management of clinically localized disease. BMJ (2013) 2.45
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays (2002) 1.76
TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med (2013) 1.49
Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol (2014) 1.46
TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A (2014) 1.31
Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate (2004) 1.12
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer (2014) 1.04
Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther (2010) 1.02
Fluid Shear Stress Sensitizes Cancer Cells to Receptor-Mediated Apoptosis via Trimeric Death Receptors. New J Phys (2013) 0.99
A Nod Scid mouse model to study human prostate cancer. Prostate Cancer Prostatic Dis (2002) 0.96
Mechanisms regulating neutrophil survival and cell death. Semin Immunopathol (2013) 0.94
Microglial MAC1 receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and subsequent neurotoxicity. J Neuroinflammation (2011) 0.94
Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis. Mol Cancer Res (2011) 0.90
Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials (2011) 0.90
Spontaneous metastasis of PC-3 cells in athymic mice after implantation in orthotopic or ectopic microenvironments. Prostate (1995) 0.90
Global effects of anchorage on gene expression during mammary carcinoma cell growth reveal role of tumor necrosis factor-related apoptosis-inducing ligand in anoikis. Cancer Res (2001) 0.90
Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc Natl Acad Sci U S A (2015) 0.88
Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans? Cancer Res (2008) 0.87
Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother (2014) 0.87
Immunotherapy in prostate cancer: review of the current evidence. Clin Transl Oncol (2014) 0.85
Tumor-targeted delivery of biologically active TRAIL protein. Cancer Gene Ther (2010) 0.85
Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway. Int J Gynecol Cancer (2007) 0.85
Leukocytes as carriers for targeted cancer drug delivery. Expert Opin Drug Deliv (2014) 0.81
Effect of terminal heat sterilization on the stability of phospholipid-stabilized submicron emulsions. Acta Pharm Nord (1992) 0.80
Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles. Bioconjug Chem (2014) 0.79
Liposome functionalization with copper-free "click chemistry". J Control Release (2015) 0.79
Using circulating tumor cells as a prognostic indicator in metastatic castration-resistant prostate cancer. Clin J Oncol Nurs (2012) 0.79
Acute toxicity of a single dose DATR, recombinant soluble human TRAIL mutant, in rodents and crab-eating macaques. Hum Exp Toxicol (2010) 0.77